CEO Executive AssistantPediatric drug development sits at a distinctive intersection of regulatory incentives, scientific complexity, community relationships, and ethical responsibility. For CEOs leading programs that include pediatric indications, whether driven by rare disease designation, PREA obligations, or a strategic decision to pursue a pediatric-first development path, the demands on your direct attention are categorically different from adult-only programs. The regulatory framework is more intricate, the patient community dynamics are unlike anything you encounter in adult indications, and the reputational stakes for how you conduct trials are higher and more visible.
What follows is a direct account of where CEO engagement in pediatric development creates leverage that cannot be generated anywhere else in the organization.
The Regulatory Incentive Landscape Requires CEO-Level Literacy
PREA, BPCA, and the Pediatric Study Plan
The Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) create both obligations and opportunities for sponsors developing drugs with potential pediatric applications. PREA generally requires sponsors of applications for new drugs or new indications to include pediatric assessments unless a waiver or deferral is granted. BPCA creates a voluntary pathway for additional market exclusivity in exchange for conducting FDA-requested pediatric studies.
CEOs who leave the management of these regulatory obligations entirely to their regulatory affairs teams frequently encounter strategic surprises. A PREA obligation that was not factored into program planning can reshape resource allocation across the entire pipeline. A BPCA Written Request that could have generated six months of additional exclusivity on a core asset can expire without being pursued because the BD team was not aware of it as a strategic tool.
Understanding the mechanics of PREA and BPCA is not about becoming a regulatory expert. It is about knowing enough to ask the right questions in program reviews: Where does each of our priority programs stand on pediatric assessment obligations? Have we evaluated the BPCA pathway for assets where the exclusivity extension would be material? What is our pediatric study plan strategy for the IND filings coming in the next eighteen months?
Rare Pediatric Disease Designation and Priority Review Vouchers
The rare pediatric disease (RPD) designation and the associated priority review voucher (PRV) represent one of the most valuable, and most underutilized, regulatory assets in the pharmaceutical toolkit. A PRV, which can be used to accelerate review of a different application or sold to another company, has transacted at values exceeding $100 million in recent years.
CEOs of companies with programs that could qualify for RPD designation should treat voucher strategy as a board-level discussion, not a regulatory filing exercise. The decision to pursue RPD designation, the timing of that pursuit, and the strategy for whether to use or sell a voucher once earned are consequential enough to warrant direct CEO engagement and board alignment.
Your pipeline governance decisions framework should explicitly account for RPD designation status as a variable in portfolio prioritization. Programs that carry voucher potential have a different risk-adjusted value profile than equivalent programs without that designation, and portfolio reviews that ignore this distinction are systematically mispricing your assets.
Patient Advocacy in Pediatric Development Is a CEO Relationship
The Parent and Caregiver Community Dynamic
Rare pediatric disease advocacy is distinct from adult disease advocacy in several important respects. The primary advocates are almost invariably parents and caregivers, not patients themselves. The urgency is acute and personal in a way that is qualitatively different from adult rare disease communities. These families are typically highly organized, scientifically literate, and capable of moving with remarkable speed to raise funds, apply regulatory pressure, and shape public perception of sponsors they view as either allies or obstacles.
CEOs who approach these communities primarily through patient affairs staff or corporate communications are missing the relationship dynamic that actually defines how these partnerships work. The leaders of the major pediatric rare disease advocacy organizations are accustomed to and expect CEO-level engagement. When they call to discuss a trial design concern, a timeline question, or a pricing anxiety, a response that routes through VP-level staff signals that their community’s priority is not commensurate with what the CEO is being asked to give.
This is not a request for unlimited availability. It is a recognition that a relatively small investment of CEO time in two to four key advocacy relationships per program can generate trust that is extraordinarily difficult to build at lower organizational levels and genuinely irreplaceable when trial recruitment challenges or adverse event communications require community support.
Building Relationships Before You Need Them
The pattern seen most consistently in successful pediatric rare disease programs is that CEO-level advocacy relationships were built during the preclinical and early clinical phases, long before trial recruitment or regulatory milestones created pressure for community engagement. Companies that begin these relationships when they need something from the community are already negotiating from a weaker position.
The investment required is manageable: participation in the major advocacy foundation conferences for your indication, direct outreach to foundation leadership when you achieve meaningful milestones, transparency in sharing program updates before they are public where appropriate, and genuine engagement with the patient registry and natural history data these organizations have often spent years collecting.
The return on this investment is not measured only in goodwill. Advocacy organizations in pediatric rare disease frequently serve as co-investigators in natural history studies, as partners in recruitment for pivotal trials, as sources of patient-reported outcome data that can support your regulatory submissions, and as vocal advocates with the FDA when your program is under review. These are material contributions to program success.
Formulation Development Is a Competitive Differentiator
The Pediatric Administration Challenge
Adult drug formulations are routinely unsuitable for pediatric administration. Tablets cannot be swallowed by infants and young children. Many oral formulations are unpalatable in doses appropriate for small body weights. Injection volumes that are routine in adults can be prohibitive in neonates. The excipients that are acceptable in adult formulations may have different safety profiles in pediatric populations, particularly in premature infants and neonates where organ system maturity affects metabolism and toxicity.
Formulation development for pediatric use is therefore not an afterthought or a line extension exercise. It is a core scientific program that requires resources, timelines, and leadership attention commensurate with its importance. CEOs who have built adult indication programs first and then attempted to extend into pediatrics without adequate formulation investment routinely encounter clinical development delays that could have been avoided with earlier planning.
The FDA’s guidance on pediatric formulation development, and the EMA’s comparable guidance under the Paediatric Regulation, both make clear that regulators expect sponsors to have engaged with pediatric-appropriate formulation challenges early in development. Reviewers notice when a pediatric program is using an adult formulation with modified dosing instructions rather than a purpose-designed pediatric presentation, and the implications for approvability and labeling can be significant.
Palatability and Acceptability Studies
One of the most practically consequential and most frequently underestimated aspects of pediatric formulation development is palatability. A drug that children reliably refuse to take, regardless of its efficacy profile, will not succeed in the real world, and regulators are increasingly attentive to acceptability data as a component of pediatric program submissions.
CEOs building pediatric programs should ensure that palatability and acceptability studies are in the development plan from the outset, not inserted as a response to clinical site feedback once trials are underway. The formulation science required to produce a pediatric-acceptable presentation of a bitter or otherwise aversive compound is substantive, and the timeline for formulation optimization, stability testing, and manufacturing process development should be planned accordingly.
Trial Design Ethics Are Not a Legal Question
The Ethical Dimensions of Pediatric Trial Enrollment
Pediatric clinical trials involve a population that cannot provide their own informed consent. The ethical framework governing pediatric research, grounded in regulations at 21 CFR Parts 50 and 56 and in the international guidance documents that inform global development programs, is more stringent than the framework for adult research. The requirement for assent from age-appropriate children, in addition to parental permission, the prohibition on greater than minimal risk research without prospect of direct benefit to subjects, and the special protections for subjects in institutional settings all create a compliance and ethical landscape that demands thoughtful program design.
CEOs who view this framework primarily as a legal and regulatory compliance matter are missing its strategic and reputational dimensions. How your company designs and conducts pediatric trials will be visible to the advocacy community, to the academic physicians who serve as investigators, to the FDA’s pediatric reviewers, and to the public. Trial designs that appear to prioritize sponsor convenience over subject welfare are noticed and remembered.
The investment in consulting with independent pediatric ethics experts during protocol design is modest relative to the cost of a protocol amendment driven by IRB concerns or an FDA clinical hold. More importantly, it reflects the values that the most successful pediatric development companies hold genuinely rather than performatively.
Surrogate Endpoint Selection and Meaningful Outcomes
Pediatric rare disease trials frequently face the challenge of defining endpoints that are both measurable in the target population and meaningful to families and clinicians. The FDA’s accelerated approval pathway, which permits approval based on surrogate or intermediate clinical endpoints, is a valuable tool in this context, but its use in pediatric populations requires careful attention to the post-marketing confirmation study obligations it creates.
Your clinical operations oversight function needs to be closely integrated with regulatory strategy when pediatric endpoints are under discussion, because the choice of primary endpoint in a pivotal trial is simultaneously a scientific question, a regulatory negotiation, and a communication to patients and families about what your program believes constitutes meaningful benefit. CEOs who stay engaged with endpoint strategy in pediatric programs are consistently better positioned to navigate the FDA’s increasing emphasis on patient-focused drug development and the agency’s expectation that pediatric outcome measures are developed with direct input from patients and caregivers.
Reputational Capital in Pediatric Development
Public and Media Scrutiny
Pediatric drug development, particularly in rare diseases affecting infants and young children, attracts a level of media and public attention that is disproportionate to the commercial scale of most programs in this space. A clinical hold, a serious adverse event, a pricing announcement, or an access decision for a pediatric therapy can generate coverage that reaches far beyond the specialist press.
This visibility is not uniformly a burden. Companies that handle pediatric programs with transparency, that communicate proactively with patient communities, and that demonstrate genuine commitment to access and affordability build reputational capital that extends well beyond the pediatric indication. The reverse is equally true: reputational damage from a pediatric program handled poorly is expensive to repair and affects commercial relationships across the portfolio.
CEOs of companies with significant pediatric programs should treat their public communication strategy for these programs as a CEO-level responsibility, not a corporate communications function. The framing of pricing decisions, the response to adverse event disclosures, and the narrative around trial access and enrollment are all communications where the CEO’s voice and values should be visible.
Pricing and Access Commitments
Gene therapies and other high-value treatments for pediatric rare diseases have generated significant public scrutiny around pricing. According to the New England Journal of Medicine’s analysis of pediatric rare disease drug economics, the tension between development cost recovery and patient access is particularly acute in conditions affecting small pediatric populations where the potential treated population is limited by definition.
CEOs navigating this terrain will find that early, public commitments to outcomes-based pricing arrangements, patient assistance programs, and collaborative access negotiations with payers generate the kind of stakeholder trust that makes subsequent commercial launch conversations more productive. These are not purely altruistic commitments; they are strategic investments in the relationships that determine whether your program achieves its commercial potential.
Building an Operating Cadence for Pediatric Programs
The CEO’s Quarterly Review Structure
A structured quarterly review cadence for pediatric programs should span five domains: regulatory strategy updates (including PREA, BPCA, and designation status), patient advocacy relationship health, formulation development milestones, clinical operations and trial performance, and commercial and access strategy. The integration of these five domains is a CEO function because the interdependencies across them require the whole-company perspective that only the CEO holds.
This review structure is not additive to a general pipeline review. It is a recognition that pediatric programs have a distinct set of strategic variables that deserve dedicated executive attention. Companies that embed pediatric considerations into standard adult program review processes consistently underweight the distinctive dynamics that make pediatric development succeed or fail.
Recruiting for Pediatric Expertise
The pediatric drug development talent pool is narrower than the adult development talent pool. Physicians and scientists with both the clinical expertise in pediatric medicine and the drug development experience required to lead programs effectively are a constrained resource. Building relationships with the academic pediatric pharmacology and pediatric medicine communities is a CEO-level investment with long-term returns.
The advisory boards, consultant relationships, and investigator networks that support pediatric programs are built over time through consistent engagement by senior company leadership. CEOs who invest in these relationships systematically build programs that are faster, better designed, and better received by regulators than programs built by companies that treat pediatric expertise as interchangeable with adult development expertise.
Pediatric drug development is among the most consequential work a pharmaceutical CEO can oversee. The science is challenging, the regulatory framework is demanding, the community relationships are irreplaceable, and the ethical standards are non-negotiable. The CEOs who lead these programs well do so because they have chosen to bring their personal attention and judgment to bear on the decisions that define whether a program serves the children and families who need it.